Supplemental Figure 1 - GSK461364 prolonged survival of mice harboring 231-BR experimental brain metastases. Mice were injected with 175,000 231-BR cells on day 0 and randomized to 4 treatment groups. On day 3 post-injection one group started treatment with 50 mg/kg GSK461364 and one group began vehicle treatment. Four days later, day 7 post-injection, the third group started treatment. Finally, on day 13 post-injection the final group started treatment. GSK461364 was administered by IP injection every other day until day 27 of the experiment. Black line; vehicle group. Red line; all treatment groups combined. Experiment 1 p=0.001 and experiment 2 p=0.026 by log-rank analysis.